Base de dados : MEDLINE
Pesquisa : D27.505.696.663.700 [Categoria DeCS]
Referências encontradas : 4939 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 494 ir para página                         

  1 / 4939 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29304272
[Au] Autor:Pandey S; Srivanitchapoom P; Kirubakaran R; Berman BD
[Ad] Endereço:Department of Neurology, G.B. Pant Hospital, New Delhi, India, 110002.
[Ti] Título:Botulinum toxin for motor and phonic tics in Tourette's syndrome.
[So] Source:Cochrane Database Syst Rev;1:CD012285, 2018 Jan 05.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Gilles de la Tourette syndrome, or Tourette's syndrome, is defined as the presence of both motor and vocal (phonic) tics for more than 12 months, that manifest before the age of 18 years, in the absence of secondary causes. Treatment of motor and phonic tics is difficult and challenging. OBJECTIVES: To determine the safety and effectiveness of botulinum toxin in treating motor and phonic tics in people with Tourette's syndrome, and to analyse the effect of botulinum toxin on premonitory urge and sensory tics. SEARCH METHODS: We searched the Cochrane Movement Disorders Group Trials Register, CENTRAL, MEDLINE, and two trials registers to 25 October 2017. We reviewed reference lists of relevant articles for additional trials. SELECTION CRITERIA: We considered all randomised, controlled, double-blind studies comparing botulinum toxin to placebo or other medications for the treatment of motor and phonic tics in Tourette's syndrome for this review. We sought both parallel group and cross-over studies of children or adults, at any dose, and for any duration. DATA COLLECTION AND ANALYSIS: We followed standard Cochrane methods to select studies, assess risk of bias, extract and analyse data. All authors independently abstracted data onto standardized forms; disagreements were resolved by mutual discussion. MAIN RESULTS: Only one randomised placebo-controlled, double-blind cross-over study met our selection criteria. In this study, 20 participants with motor tics were enrolled over a three-year recruitment period; 18 (14 of whom had a diagnosis of Tourette's syndrome) completed the study; in total, 21 focal motor tics were treated. Although we considered most bias domains to be at low risk of bias, the study recruited a small number of participants with relatively mild tics and provided limited data for our key outcomes. The effects of botulinum toxin injections on tic frequency, measured by videotape or rated subjectively, and on premonitory urge, are uncertain (very low-quality evidence). The quality of evidence for adverse events following botulinum toxin was very low. Nine people had muscle weakness following the injection, which could have led to unblinding of treatment group assignment. No data were available to evaluate whether botulinum injections led to immunoresistance to botulinum. AUTHORS' CONCLUSIONS: We are uncertain about botulinum toxin effects in the treatment of focal motor and phonic tics in select cases, as we assessed the quality of the evidence as very low. Additional randomised controlled studies are needed to demonstrate the benefits and harms of botulinum toxin therapy for the treatment of motor and phonic tics in patients with Tourette's syndrome.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Fármacos Neuromusculares/uso terapêutico
Tiques/tratamento farmacológico
Síndrome de Tourette/tratamento farmacológico
[Mh] Termos MeSH secundário: Toxinas Botulínicas Tipo A/efeitos adversos
Seres Humanos
Fármacos Neuromusculares/efeitos adversos
Tiques/etiologia
Fatores de Tempo
Síndrome de Tourette/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Neuromuscular Agents); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012285.pub2


  2 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29235317
[Au] Autor:Malcmacher L; Kosinski T
[Ti] Título:Bruxism, Botox, and Dental Implants.
[So] Source:Dent Today;36(4):94, 96-7, 2017 Apr.
[Is] ISSN:8750-2186
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Bruxismo/tratamento farmacológico
Implantes Dentários
Fármacos Neuromusculares/uso terapêutico
Desgaste dos Dentes/terapia
[Mh] Termos MeSH secundário: Adulto
Bruxismo/diagnóstico
Tomografia Computadorizada de Feixe Cônico
Feminino
Seres Humanos
Exame Físico
Desgaste dos Dentes/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dental Implants); 0 (Neuromuscular Agents); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  3 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29280866
[Au] Autor:El-Khoury JS; Jabbour SF; Awaida CJ; Rayess YA; Kechichian EG; Nasr MW
[Ad] Endereço:Beirut, Lebanon From the Departments of Plastic and Reconstructive Surgery and Dermatology, Faculty of Medicine, Saint-Joseph University Hotel Dieu de France Hospital.
[Ti] Título:The Impact of Botulinum Toxin on Brow Height and Morphology: A Randomized Controlled Trial.
[So] Source:Plast Reconstr Surg;141(1):75-78, 2018 01.
[Is] ISSN:1529-4242
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Previous reports have objectively demonstrated the efficacy of botulinum toxin for brow elevation. No clinical trial has compared the variation of the eyebrow shape and height when the lateral eyebrow depressors are injected alone or in combination with the medial eyebrow depressors. METHODS: A prospective, randomized, controlled study was designed to evaluate and compare the effect of two different botulinum toxin injection techniques on brow shape and position. Patients were divided into two groups. AbobotulinumtoxinA was injected in the lateral eyebrow depressors alone (group 1) or in both the lateral and medial eyebrow depressors (group 2). Objective eyebrow measurements were performed using standardized preinjection and postinjection photographs. Patient satisfaction was also evaluated. RESULTS: Fifteen patients (30 eyebrows) were included in each group. The brow elevated by 0.6 to 2.1 mm at all positions in group 1. In group 2, the brow elevated from the medial limbus to the lateral edge of the brow (1 to 1.7 mm), with no changes at the level of the medial brow and canthus. When comparing the two injection techniques, the authors found a statistically significant difference in the change of eyebrow height at the level of the medial brow, medial canthus, and lateral brow edge. Ninety-seven percent of patients were satisfied with their results. CONCLUSION: Different eyebrow injection techniques yield different elevation patterns. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/administração & dosagem
Técnicas Cosméticas
Sobrancelhas
Fármacos Neuromusculares/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Sobrancelhas/anatomia & histologia
Feminino
Seres Humanos
Injeções Intramusculares
Avaliação de Resultados (Cuidados de Saúde)
Satisfação do Paciente/estatística & dados numéricos
Estudos Prospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A); EC 3.4.24.69 (abobotulinumtoxinA)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1097/PRS.0000000000003919


  4 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29078865
[Au] Autor:Khawaja SN; Scrivani SJ; Holland N; Keith DA
[Ad] Endereço:Resident, Division of Oral and Maxillofacial Pain, Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, Boston, MA; and Post-Graduate Fellow, Harvard School of Dental Medicine, Harvard University, Boston, MA. Electronic address: khawajashehryar@gmail.com.
[Ti] Título:Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study.
[So] Source:J Oral Maxillofac Surg;75(11):2307-2315, 2017 Nov.
[Is] ISSN:1531-5053
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Masticatory muscle pain disorders respond well to conservative therapy; however, in some patients the pain becomes refractory. Botulinum toxin type A (BoT-A) therapy has been shown to be an effective modality in the management of refractory headache disorders. Conversely, there are conflicting reports in the literature regarding the efficacy, safety, and predictors of therapeutic response to BoT-A therapy for management of refractory masticatory muscle pain. MATERIALS AND METHODS: We performed a retrospective chart review of patients who underwent at least 2 injection cycles of 100 U of BoT-A for refractory masticatory myalgia in the Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, between May 2012 and June 2016. Information regarding demographic, diagnostic, and therapeutic characteristics was extracted and analyzed. The χ test was used for analysis between independent and dependent variables. Forward step-wise-type logistic regression analysis was conducted to determine the predictors of outcome. RESULTS: Among 116 participants, 30.6% reported significant relief in pain for a mean period of 10.1 weeks. A total of 16.4% of participants reported at least 1 adverse effect. The effectiveness of the BoT-A therapy was found to be statistically associated with the presence of muscle hypertrophy (P = .004), range of motion (P = .02), concurrent use of opioid analgesics (P = .003), and local anesthetic trigger-point injections (P = .003). Logistic regression analyses suggested that the presence of muscle hypertrophy and occurrence of adverse effects were predictors of positive outcome. On the contrary, concurrent use of opioid analgesics was found to be a predictor for no or minimal relief. CONCLUSIONS: BoT-A therapy provides significant relief for approximately one third of patients with refractory masticatory muscle pain. Therapy is associated with a mild risk of adverse effects. The presence of muscle hypertrophy, occurrence of an adverse effect, and concurrent use of opioid analgesics were found to be predictors of outcome response.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Músculos da Mastigação
Mialgia/tratamento farmacológico
Fármacos Neuromusculares/uso terapêutico
[Mh] Termos MeSH secundário: Toxinas Botulínicas Tipo A/efeitos adversos
Feminino
Previsões
Seres Humanos
Masculino
Meia-Idade
Fármacos Neuromusculares/efeitos adversos
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; D; IM
[Da] Data de entrada para processamento:171029
[St] Status:MEDLINE


  5 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064991
[Au] Autor:Jones DH; Kerscher M; Geister T; Hast MA; Weissenberger P
[Ad] Endereço:*Skin and Laser Physicians of Beverly Hills, Beverly Hills, California; †Division of Cosmetic Science, University of Hamburg, Hamburg, Germany; ‡Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany; §Merz North America, Inc., Raleigh, North Carolina.
[Ti] Título:Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses From Randomized, Double-Blind Pivotal Studies.
[So] Source:Dermatol Surg;43 Suppl 2:S235-S241, 2017 Nov.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Males are increasingly seeking minimally invasive cosmetic procedures such as botulinum toxin injection. However, few studies have specifically examined the efficacy of such procedures among men. OBJECTIVE: To assess the efficacy of incobotulinumtoxinA for treating glabellar frown lines (GFLs) in men. METHODS: Three incobotulinumtoxinA studies were included in post hoc analyses of responder rates: 2 pivotal Phase 3 US registration studies for GFLs (n = 55 males in a pooled analysis) and a European pivotal Phase 3 study for upper facial lines (UFLs; n = 21 males). RESULTS: In the pooled analysis of Phase 3 GFL studies, 55.9% of males and 81.4% of females were responders on the Facial Wrinkle Scale (FWS) at 30 days. Similarly, 54.5% and 88.0% of males and females, respectively, treated for GFLs in the upper facial line study were responders on the Merz Aesthetics Scales (MAS) at 30 days. Lower proportions of male responders on the Facial Wrinkle Scale /Merz Aesthetics Scales were consistent with results from onabotulinumtoxinA and abobotulinumtoxinA GFL studies. CONCLUSION: Compared with females, males demonstrate lower response rates on wrinkle severity scales in studies on all 3 available botulinum toxins. Variations in treatment response are potentially associated with key male anatomic differences (e.g., muscle mass). Results emphasize the need for customized treatment plans.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Testa
Fármacos Neuromusculares/uso terapêutico
Envelhecimento da Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Neuromuscular Agents); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A); EC 3.4.24.69 (incobotulinumtoxinA)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001295


  6 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064979
[Au] Autor:Solish N
[Ad] Endereço:Dermatology, University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:Commentary on Aesthetic Treatment With Botulinum Toxin.
[So] Source:Dermatol Surg;43 Suppl 2:S157, 2017 11.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Toxinas Botulínicas
Fármacos Neuromusculares
[Mh] Termos MeSH secundário: Toxinas Botulínicas Tipo A
Estética
Seres Humanos
Envelhecimento da Pele
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001371


  7 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064978
[Au] Autor:Green JB; Keaney TC
[Ad] Endereço:*Skin Associates of South Florida, Coral Gables, Florida; †Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida; ‡SkinDC, Arlington, Virginia; §Department of Dermatology, George Washington Hospital, Washington, DC.
[Ti] Título:Aesthetic Treatment With Botulinum Toxin: Approaches Specific to Men.
[So] Source:Dermatol Surg;43 Suppl 2:S153-S156, 2017 Nov.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Men are increasingly seeking aesthetic treatment with neuromodulators. OBJECTIVE: To successfully treat the male patient, it is imperative to understand anatomical and dosing differences from his, perhaps more familiar, female counterpart. CONCLUSION: After reading this review including male-specific botulinum toxin technique tips derived from their own practices, the authors hope injectors are able to approach their male patients with increased confidence to deliver superior outcomes.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Técnicas Cosméticas
Estética
Face
Fármacos Neuromusculares/uso terapêutico
Envelhecimento da Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001375


  8 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29059315
[Au] Autor:Issaho DC; Carvalho FRS; Tabuse MKU; Carrijo-Carvalho LC; de Freitas D
[Ad] Endereço:Hospital de Olhos do Parana, Curitiba, Brazil.
[Ti] Título:The Use of Botulinum Toxin to Treat Infantile Esotropia: A Systematic Review With Meta-Analysis.
[So] Source:Invest Ophthalmol Vis Sci;58(12):5468-5476, 2017 Oct 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: The purpose of this review was to examine the efficacy of botulinum toxin in the treatment of infantile esotropia and to evaluate the average response of BT and its complication rates. Methods: A research was performed in the Latin American and Caribbean Literature on Health Sciences (LILACS), MEDLINE, and Cochrane Central Register of Controlled Trial (CENTRAL). The database was searched between December 28, 2016 and January 30, 2017. The selection was restricted to articles published in English, Spanish, or Portuguese. There were no date restrictions in the search. Results: Nine studies were eligible for inclusion. The grouped success rate of BT treatment in infantile esotropia was 76% (95% confidence interval [CI]: 61%-89%). For the success rate, I2 of 94.25% was observed, indicating a high heterogeneity (P < 0.001). The complication rates were also analyzed. The grouped consecutive exotropia (XT) rate was 1% (95% CI: 0%-2%). The grouped ptosis rate was 27% (95% CI: 21%-33%). The grouped vertical deviation rate was 12% (95% CI: 4%-22%). The mean change of the deviation after BT injection was -30.7 (95% CI: -37.7, -23.8), demonstrating a significant improvement in alignment. Conclusions: Botulinum toxin injection into medial recti muscles reveals to be a safe procedure and a valuable alternative to strabismus surgery in congenital esotropia, especially in moderate deviations.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Esotropia/tratamento farmacológico
Fármacos Neuromusculares/uso terapêutico
[Mh] Termos MeSH secundário: Toxinas Botulínicas Tipo A/administração & dosagem
Toxinas Botulínicas Tipo A/efeitos adversos
Pré-Escolar
Seres Humanos
Lactente
Injeções Intramusculares
Fármacos Neuromusculares/administração & dosagem
Fármacos Neuromusculares/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171024
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22576


  9 / 4939 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953721
[Au] Autor:de Maio M; DeBoulle K; Braz A; Rohrich RJ; Alliance for the Future of Aesthetics Consensus Committee
[Ad] Endereço:São Paulo, Brazil; Aalst, Belgium; Rio de Janeiro, Brazil; and Dallas, Texas From the Clinica Dr. Maurício de Maio; the Aalst Dermatology Clinic, private practice; and the University of Texas Southwestern Medical Center.
[Ti] Título:Facial Assessment and Injection Guide for Botulinum Toxin and Injectable Hyaluronic Acid Fillers: Focus on the Midface.
[So] Source:Plast Reconstr Surg;140(4):540e-550e, 2017 Oct.
[Is] ISSN:1529-4242
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This second article of a three-part series addresses techniques and recommendations for aesthetic treatment of the midface. Injectable fillers are important for rejuvenation of the midface by replacing lost volume and providing structural support; neuromodulators play a smaller role in this facial region. Fillers are used for volumization and contouring of the midface regions, including the upper cheek and lid-cheek junction and the submalar and preauricular areas. Also, treatment of the frontonasal angle, the dorsum, the nasolabial angle, and the columella may be used to shape and contour the nose. Neuromodulators may be used to treat bunny lines and for elevation of the nasal tip. The midface is considered an advanced area for treatment, and injectors are advised to obtain specific training, particularly when injecting fillers near the nose, because of the risk of serious complications, including blindness and necrosis. Injections made in the midcheek must be performed with caution to avoid the infraorbital artery.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/administração & dosagem
Face/anatomia & histologia
Ácido Hialurônico/administração & dosagem
Guias de Prática Clínica como Assunto
Ritidoplastia/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Injeções
Fármacos Neuromusculares/administração & dosagem
Viscossuplementos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Neuromuscular Agents); 0 (Viscosupplements); 9004-61-9 (Hyaluronic Acid); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/PRS.0000000000003716


  10 / 4939 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953646
[Au] Autor:Türk Börü Ü; Duman A; Bölük C; Coskun Duman S; Tasdemir M
[Ad] Endereço:aDepartment of Neurology, Dr. Lütfi Kirdar Kartal Training and Research Hospital bDepartment of Neurology, Maltepe State Hospital cDepartment of Public Health, Bezmialem University, Istanbul, Turkey.
[Ti] Título:Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up.
[So] Source:Medicine (Baltimore);96(39):e8133, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Botulinum toxin type-A (BTX-A) has been successfully utilized to treat trigeminal neuralgia. In this study, through the use of a new technique, the efficacy of the injection of BTX-A to the maxillary and mandibular nerves was evaluated. METHODS: A total of 27 patients were injected with 100 Units of BTX-A to the maxillary and mandibular nerves. Visual analogue scale score and pain frequency were assessed before treatment and at the first week, second month, and sixth month after treatment. Patients with ≥50% reduction in mean pain score at the second and sixth month were defined as responders. RESULTS: A total of 27 patients were included in the study. BTX-A significantly reduced pain intensity and pain attack frequency at the first week, second month, and sixth month after treatment. At the second month, 74.1% of patients, at the sixth month, 88.9% of patients responded to treatment. Forty-four percent of patients did not experience any pain at the sixth month. The mean recurrence period was 87.7 ±â€Š20.4. BTX-A was well tolerated and showed few treatment-related adverse events. CONCLUSION: Injection to the maxillary and mandibular roots seems to be a highly effective method. In the event of recurrence, after each injection, the pain severity and attack frequency decreased.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/administração & dosagem
Fármacos Neuromusculares/administração & dosagem
Neuralgia do Trigêmeo/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seguimentos
Seres Humanos
Injeções
Masculino
Nervo Mandibular
Nervo Maxilar
Meia-Idade
Medição da Dor
Recidiva
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008133



página 1 de 494 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde